Module

Epidemiology, Screening, and Biomarkers for Prostate Cancer

Source: Prostate Cancer Annual Update 2006

Epidemiology, Screening, and Biomarkers for Prostate Cancer

Program Director: E. David Crawford, MD

Faculty:
Bob Djavan, MD, PhD

CME CREDIT INFORMATION

Release Date: 03/22/06

Expiration Date: 03/21/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss international trends and patterns for prostate cancer, with special emphasis on the epidemiology of this disease in the US population
Describe the advantages and disadvantages of PSA screening
Summarize ongoing studies involving novel biomarkers for prostate cancer

Topics covered include:

Introduction
Geographic and Environmental Variations
Hereditary Factors
A Viral Link to Prostate Cancer?
PSA Screening and Its Effect
Is PSA Testing Still Necessary?
Prostate Cancer Survival
Biomarkers
Novel Biomarkers
Profiling of Gene Expression
Biopsy for Detection of Prostate Cancer
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.